CatalYm
PrivateLast Round
Series D
Jul 16, 2024
Total Funding Raised
$265.94M
Company Overview
CatalYm is a biopharmaceutical company that develops proprietary immunotherapies designed to overcome cancer resistance to existing oncology treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CatalYm Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
CatalYm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jul 16, 2024 | ||||
| Series C | Nov 22, 2022 | ||||
| Series B | Nov 10, 2020 | ||||
| Seed | Aug 1, 2016 |
Key People
Founding team and executive leadership
CatalYm Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A, Series D, Series C |
| Omega Funds | Series D |
| Forbion | Series D, Series C, Series B, Series A, Seed |
| Gilde Healthcare | Series D |
| Vesalius Biocapital Partners | Series D, Series C, Series B |
| Wachstumsfonds Bayern | Series B |
| Canaan Partners | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Lead antibody visugromab advances to Phase 2b studies for solid tumors.
- Apr 25, 2025
New data on GDF-15 blockade technology to be presented at AACR 2025.
CatalYm Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about CatalYm's valuation, stock price, and market status.